<DOC>
	<DOC>NCT00259233</DOC>
	<brief_summary>12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.</brief_summary>
	<brief_title>The Role of Peptide YY (PYY)in Inhibiting Food Intake.</brief_title>
	<detailed_description />
	<criteria>Normal weight (BMI: 1823 kg/m2) or 12 overweight/obese (BMI: 2740 kg/m2) Body weight fluctuations &lt; 5 kg over the past 2 months. Blood pressure normal to mildly hypertensive(&lt;159/99 mm Hg) Nonelite athletes and not planning to change physical activity during the study. Any physiological or psychological illnesses that could influence the study results. Regular use of medicine. Smoking defined as &lt;1 cigarette per day. Substance abuse or dependence. Blood donation within the past 3 months before entering the study. Drinking &gt;21 alcoholic units/week. Food allergies. Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>